Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2005-12-01
2009-11-10
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C530S391100
Reexamination Certificate
active
07615224
ABSTRACT:
Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, α-iduronidase, α-glucosidase, β-glucosidase, 2-sulphatase, 4-sulphatase, α-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.
REFERENCES:
patent: 2007/0072243 (2007-03-01), Meikle et al.
patent: WO 97/44668 (1997-11-01), None
patent: WO 00/55632 (2000-09-01), None
patent: WO 03/092601 (2003-04-01), None
patent: WO 2004/088322 (2004-03-01), None
PCT International Search Report and written opinion Dated Feb. 6, 2006.
Brooks Douglas Alexander
Dean Caroline
Hopwood John Joseph
Meikle Peter John
Jackson Walker L.L.P.
Ouspenski Ilia
Women's and Children's Hospital
LandOfFree
Multiplex-bead complex for determination of lysosomal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiplex-bead complex for determination of lysosomal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiplex-bead complex for determination of lysosomal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4121910